Disclosures: Stefano D'Anna: Nothing to Disclose, Romina Salpini: Nothing to Disclose, Elisabetta Degasperi: Gilead: Speaking and Teaching, Roche: Advisor, Abbvie: Speaking and Teaching, Leonardo Duca: Nothing to Disclose, Maria Paola Anolli: Nothing to Disclose, Lorenzo Piermatteo: Nothing to Disclose, Dana Sambarino: Nothing to Disclose, Marta Borghi: Nothing to Disclose, Francesca Ceccherini Silberstein: Nothing to Disclose, Floriana Facchetti: Nothing to Disclose, Riccardo Perbellini: Nothing to Disclose, valentina svicher: Nothing to Disclose, Pietro Lampertico: ROCHE PHARMA/DIAGNOSTICS, GILEAD SCIENCES, GSK, ABBVIE, JANS: Advisor 884 GUT MYCOBIOME IN THE SPECTRUM OF METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): FROM MASH TO HEPATOCELLULAR CARCINOMA Mario Alvares-da-Silva 1 Cassio Perlin 1 Melina Keingeski 1 Bruno Basso 1 Juliane Medeiros 2 Francis Borges 2 Carolina Uribe-Cruz 3 , 1 Universidade Federal do Rio Grande do Sul, 2 Universidade Federal de Juiz de Fora, 3 Universidad Catolica de Misiones Background: Gut microbiome (GM) dysbiosis is associated with the development and progression of metabolic-dysfunction associated steatotic liver disease (MASLD) and steatohepatitis (MASH)
Metformin treatment had a smaller and non-statistically significant effect in LC female PBMCs (Supplementary Figure S7B, CD4 p = 0.31, CD8 p = 0.42), where treatment reduced on average CD4 and CD8 T cell proliferation in female LC donors by 5.2% and 7.6% respectively
C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey
Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner
PCs treatment reduced MFG-E8, phospho-ERK1/2, phospho-Akt, and phospho-GSK-3 levels in db/db mouse kidneys, indicating MFG-E8s influence on the progression of diabetic nephropathy
4559-C NEXT GENERATION HEPQUANT TESTS PREDICT CLINICAL OUTCOME IN PRIMARY SCLEROSING CHOLANGITIS Michael P
